Lucid Diagnostics Inc. Common Stock earnings per share and revenue
On 12. Nov. 2025, LUCD reported earnings of -0.10 USD per share (EPS) for Q3 25, beating the estimate of -0.11 USD, resulting in a 11.03% surprise. Revenue reached 1.21 million, compared to an expected 1.38 million, with a -12.52% difference. The market reacted with a +6.73% price change (close before vs. close after earnings).
Looking ahead to Q4 25, 8 analysts forecast an EPS of -0.10 USD, with revenue projected to reach 1.49 million USD, implying an increase of 0.00% EPS, and increase of 22.68% in Revenue from the last quarter.
Industry Peers’ Earnings
Industry Peers' Earnings displays EPS earnings data from companies in the same industry. Click on a card to view more details.
AngioDynamics, Inc.
Report Date
06. Jan. 2026 For Q2 26
Estimate
-$0.10
Aktuell
$0.00
Überraschung
+100.00%
FAQ
What were Lucid Diagnostics Inc. Common Stock's earnings and revenue for the latest quarter Q3 2025?
For Q3 2025, Lucid Diagnostics Inc. Common Stock reported EPS of -$0.10, beating estimates by 11.03%, and revenue of $1.21M, -12.52% below expectations.
How did the market react to Lucid Diagnostics Inc. Common Stock's Q3 2025 earnings?
The stock price moved up 6.73%, changed from $1.04 before the earnings release to $1.11 the day after.
When is Lucid Diagnostics Inc. Common Stock expected to report next?
The next earning report is scheduled for 23. März 2026.
What are the forecasts for Lucid Diagnostics Inc. Common Stock's next earnings report?
Based on 8
analysts, Lucid Diagnostics Inc. Common Stock is expected to report EPS of -$0.10 and revenue of $1.49M for Q4 2025.